Advanced head and neck cancer: Low-dose, split-course radiation therapy and simultaneous infusion of 5-fluorouracil and cisplatin

J. A. Stryker, Harold Harvey, J. R. Houck, E. K. Manders, J. J. Bradfield

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Twenty-three patients with advanced untreated head and neck cancer, nine patients with recurrent cancer, and six patients with recurrent cancer who underwent surgery and had postoperative persistence of tumor were treated with three 2-week courses of irradiation (1,500 cGy in 10 fractions each) concurrently with cisplatin and a 5-day infusion of 5-fluorouracil. A fourth 2-week course of irradiation (2,000 cGy in 10 fractions) brought the final tumor dose to 6,500 cGy. Twenty patients in the untreated group and three patients in the recurrent group (33%) had a complete response. There were 10 local recurrences in the untreated group (43%), seven in the recurrent group (78%), and three in the persistent group (50%). At 17 months after the start of treatment, the survival rate for the untreated patients was 51%, for the patients in the recurrent group it was 11%, and for the patients in the persistent group it was 20% (P = .03). Most patients experienced toxicity, including nausea, vomiting, weight loss, and mucositis. Clinical trials are necessary to determine whether simultaneous chemotherapy and radiation therapy is an improved method of treatment for advanced head and neck cancer.

Original languageEnglish (US)
Pages (from-to)567-571
Number of pages5
JournalRadiology
Volume176
Issue number2
DOIs
StatePublished - Jan 1 1990

Fingerprint

Head and Neck Neoplasms
Fluorouracil
Cisplatin
Radiotherapy
Neoplasms
Mucositis
Nausea
Vomiting
Weight Loss
Survival Rate
Clinical Trials
Recurrence
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Stryker, J. A. ; Harvey, Harold ; Houck, J. R. ; Manders, E. K. ; Bradfield, J. J. / Advanced head and neck cancer : Low-dose, split-course radiation therapy and simultaneous infusion of 5-fluorouracil and cisplatin. In: Radiology. 1990 ; Vol. 176, No. 2. pp. 567-571.
@article{b5a0f5a898ea4967bdf5d439e5faffff,
title = "Advanced head and neck cancer: Low-dose, split-course radiation therapy and simultaneous infusion of 5-fluorouracil and cisplatin",
abstract = "Twenty-three patients with advanced untreated head and neck cancer, nine patients with recurrent cancer, and six patients with recurrent cancer who underwent surgery and had postoperative persistence of tumor were treated with three 2-week courses of irradiation (1,500 cGy in 10 fractions each) concurrently with cisplatin and a 5-day infusion of 5-fluorouracil. A fourth 2-week course of irradiation (2,000 cGy in 10 fractions) brought the final tumor dose to 6,500 cGy. Twenty patients in the untreated group and three patients in the recurrent group (33{\%}) had a complete response. There were 10 local recurrences in the untreated group (43{\%}), seven in the recurrent group (78{\%}), and three in the persistent group (50{\%}). At 17 months after the start of treatment, the survival rate for the untreated patients was 51{\%}, for the patients in the recurrent group it was 11{\%}, and for the patients in the persistent group it was 20{\%} (P = .03). Most patients experienced toxicity, including nausea, vomiting, weight loss, and mucositis. Clinical trials are necessary to determine whether simultaneous chemotherapy and radiation therapy is an improved method of treatment for advanced head and neck cancer.",
author = "Stryker, {J. A.} and Harold Harvey and Houck, {J. R.} and Manders, {E. K.} and Bradfield, {J. J.}",
year = "1990",
month = "1",
day = "1",
doi = "10.1148/radiology.176.2.2367676",
language = "English (US)",
volume = "176",
pages = "567--571",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "2",

}

Advanced head and neck cancer : Low-dose, split-course radiation therapy and simultaneous infusion of 5-fluorouracil and cisplatin. / Stryker, J. A.; Harvey, Harold; Houck, J. R.; Manders, E. K.; Bradfield, J. J.

In: Radiology, Vol. 176, No. 2, 01.01.1990, p. 567-571.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Advanced head and neck cancer

T2 - Low-dose, split-course radiation therapy and simultaneous infusion of 5-fluorouracil and cisplatin

AU - Stryker, J. A.

AU - Harvey, Harold

AU - Houck, J. R.

AU - Manders, E. K.

AU - Bradfield, J. J.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Twenty-three patients with advanced untreated head and neck cancer, nine patients with recurrent cancer, and six patients with recurrent cancer who underwent surgery and had postoperative persistence of tumor were treated with three 2-week courses of irradiation (1,500 cGy in 10 fractions each) concurrently with cisplatin and a 5-day infusion of 5-fluorouracil. A fourth 2-week course of irradiation (2,000 cGy in 10 fractions) brought the final tumor dose to 6,500 cGy. Twenty patients in the untreated group and three patients in the recurrent group (33%) had a complete response. There were 10 local recurrences in the untreated group (43%), seven in the recurrent group (78%), and three in the persistent group (50%). At 17 months after the start of treatment, the survival rate for the untreated patients was 51%, for the patients in the recurrent group it was 11%, and for the patients in the persistent group it was 20% (P = .03). Most patients experienced toxicity, including nausea, vomiting, weight loss, and mucositis. Clinical trials are necessary to determine whether simultaneous chemotherapy and radiation therapy is an improved method of treatment for advanced head and neck cancer.

AB - Twenty-three patients with advanced untreated head and neck cancer, nine patients with recurrent cancer, and six patients with recurrent cancer who underwent surgery and had postoperative persistence of tumor were treated with three 2-week courses of irradiation (1,500 cGy in 10 fractions each) concurrently with cisplatin and a 5-day infusion of 5-fluorouracil. A fourth 2-week course of irradiation (2,000 cGy in 10 fractions) brought the final tumor dose to 6,500 cGy. Twenty patients in the untreated group and three patients in the recurrent group (33%) had a complete response. There were 10 local recurrences in the untreated group (43%), seven in the recurrent group (78%), and three in the persistent group (50%). At 17 months after the start of treatment, the survival rate for the untreated patients was 51%, for the patients in the recurrent group it was 11%, and for the patients in the persistent group it was 20% (P = .03). Most patients experienced toxicity, including nausea, vomiting, weight loss, and mucositis. Clinical trials are necessary to determine whether simultaneous chemotherapy and radiation therapy is an improved method of treatment for advanced head and neck cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025350435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025350435&partnerID=8YFLogxK

U2 - 10.1148/radiology.176.2.2367676

DO - 10.1148/radiology.176.2.2367676

M3 - Article

C2 - 2367676

AN - SCOPUS:0025350435

VL - 176

SP - 567

EP - 571

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 2

ER -